Fermion

Fermion, founded by Deng Daiguo, a computer science Ph.D. from Sun Yat-sen University, in August 2018, positions itself as a technology-driven new pharmaceutical company. It integrates multiple disciplines such as biology, medicinal chemistry, and computer science, applying artificial intelligence technologies like deep learning, reinforcement learning, generative adversarial networks, big data, and knowledge graphs to new drug development. This enhances R&D efficiency and provides more and better treatment options for diseases, pushing the boundaries of drug discovery. Based on AI technology, Fermion's self-developed drug design platform Fulmz Drug Studio has achieved multiple technological innovations in target prediction, customized generation of molecular libraries, virtual screening, ADMET prediction, and lead optimization. It has already helped the company deliver on multiple projects, effectively improving R&D efficiency and reducing costs.